MarketPulse

recurrence reduction

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences' GLSI-100 Data Gets ASCO Platform; 70-80% Recurrence Reduction Shown

Greenwich LifeSciences' GLSI-100 breast cancer immunotherapy receives ASCO 2026 abstract acceptance, showing 70-80% recurrence reduction in Phase III trial.
GLSIGLSI-100FLAMINGO-01
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Expands FLAMINGO-01 Trial With City of Hope, Advances Breast Cancer Immunotherapy

Greenwich LifeSciences expands FLAMINGO-01 trial with City of Hope, growing sites to 190-200. Preliminary data shows 70-80% recurrence reduction in breast cancer immunotherapy study.
GLSIbreast cancerGLSI-100
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Presents FLAMINGO-01 Trial Data at AACR 2026 Conference

Greenwich LifeSciences presents FLAMINGO-01 Phase III trial data at AACR 2026, showing 80% recurrence reduction. Non-HLA-A*02 arm fully enrolled with 250 patients.
GLSIbreast cancerGLSI-100